Neurizon Secures Five-Year Monepantel Supply for ALS Drug NUZ-001; Stock Rises

Neurizon announced a five-year supply agreement for monepantel, a key ingredient for its investigational Amyotrophic Lateral Sclerosis (ALS) drug NUZ-001, on June 17, 2026. The strategic partnership aims to ensure a stable and long-term supply, sending the company's stock higher following the news. The agreement, made with a leading global supplier, is critical for the continued development and potential commercialization of NUZ-001. This long-term commitment mitigates supply chain risks for the drug candidate, which is currently in clinical development. NUZ-001 is being developed as a potential treatment for ALS, a progressive neurodegenerative disease. The secured supply of monepantel is a crucial step in advancing Neurizon's pipeline for this debilitating condition.